胸腺肽α1对原发性肝癌TACE术前术后T淋巴细胞亚群的影响

Effect of Alpha-1-thymosin on T-lymphocyte Subpopulations in Hepatocellular Carcinoma Patients before and after Transcatheter Arterial Chemoemb

目的探讨胸腺肽α1在原发性肝癌(TACE)术前术后改善免疫功能的作用。方法原发性肝癌37例,随机分为治疗组19例和对照组18例,治疗组在TACE术前给予胸腺肽α11.6 mg,3次/周,两组化疗方案相同,在TACE术前及TACE术后2周、4周后分别抽血检测。结果TACE术后2周时两组CD3均有不同程度的下降,但4周时治疗组恢复到原先水平,而对照组仍持续下降,其差异有统计学意义,P<0.05;CD4在4周时两组间差异有统计学意义;CD8两组均有不同程度的升高,但两组间无统计学意义;CD4/CD8和NK两组均有不同程度的下降,其差异有统计学意义。结论胸腺肽α1可提高恶性肿瘤患者的免疫功能,在治疗前给药效果更佳。

Objective To evaluate the therapeutic potential of the immunostimulating adjuvant alpha-1-thymosin in patients with hepatocellular carcinoma before and after TACE. Methods Thirty-seven patients with hepatocellular carcinoma were randomly divided into treatment groups （19） and control groups （ 18 ）. Treatment groups were treated with alpha-1-thymosin 1.6 mg subcutaneously thrice per week before transcatheter arterial chemoembolization. Both groups had the same chemotherapy, T- lymphocyte subpopulations were examined before TACE and also in the second, fourth week after TACE. Results CD3 of both groups have varying degrees of decline in the second week after TACE, and treatment groups restored to the original level in the fourth week, but control groups declined constantly and had significant differences, P 〈 0.05. There were significant differences of CD4 of two groups in the fourth week ; CD8 of two groups have varying degrees of increases but had no significances ; CD4/CD8 and NK have varying degrees of decline and had significant differences. Conclusion Alpha-1-thymosin had immunostimulating functions in patients with hepatocellular carcinoma, and can achieve better effects if treated before TACE.